Bibliografia UJ CM

1/9
John C. Byrd, Peter Hillmen, Paolo Ghia, Arnon P. Kater, Asher Chanan-Khan, Richard R. Furman, Susan O'Brien, Mustafa Nuri Yenerel, Arpad Illés, Neil Kay, Jose A. Garcia-Marco, Anthony Mato, Javier Pinilla-Ibarz, John F. Seymour, Stephane Lepretre, Stephan Stilgenbauer, Tadeusz Robak, Wayne Rothbaum, Raquel Izumi, Ahmed Hamdy, Priti Patel, Kara Higgins, Sophia Sohoni, Wojciech Jurczak.
Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia : results of the first randomized phase III trial.
Journal of Clinical Oncology
2021 : Vol. 39, nr 31, s. 3441-3452, il., bibliogr. 37 poz.
Autor korespondencyjny: John C. Byrd.
Open Access Creative Commons Attribution License CC-BY-NC ND 4.0.
p-ISSN: 0732-183X
e-ISSN: 1527-7755
AZ
ORG
AIF
IF: 50.739
Adres url:
Streszczenie w PubMed:
2/9
Philipp Bernhard Staber, Wojciech Jurczak, Richard Greil, Vladan Vucinic, Jan Moritz Middeke, Marco Montillo, Talha Munir, Peter Neumeister, Johannes Schetelig, Stephan Stilgenbauer, Frank Striebel, Maren Dirnberger-Hertweck, Johannes Weirather, Wolfram Brugger, Peter Kelemen, Clemens-Martin Wendtner, Jennifer Ann Woyach.
Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor.
Leukemia & Lymphoma
2021 : Vol. 62, nr 14, s. 3440-3451, il., bibliogr. 32 poz., abstr.
Autor korespondencyjny: Philipp Bernhard Staber.
Both authors contributed equally as first authors: Philipp Bernhard Staber and Wojciech Jurczak.
p-ISSN: 1042-8194
e-ISSN: 1029-2403
AZ
ORG
AIF
IF: 2.996
Adres url:
Streszczenie w PubMed:
3/9
Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, Peter Hillmen, John F. Seymour, Steven Coutre, Wojciech Jurczak, Stephen P. Mulligan, Anna Schuh, Sarit Assouline, Clemens-Martin Wendtner, Andrew W. Roberts, Matthew S. Davids, Johannes Bloehdorn, Talha Munir, Sebastian Bottcher, Lang Zhou, Ahmed Hamed Salem, Monali Desai, Brenda Chyla, Jennifer Arzt, Su Young Kim, Maria Verdugo, Gary Gordon, Michael Hallek, William G. Wierda.
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial .
Journal of Clinical Oncology
2018 : Vol. 36, nr 9, s. 1973-1980
Autor korespondencyjny: Stephan Stilgenbauer.
p-ISSN: 0732-183X
AZ
ORG
AIF
IF: 28.245
Adres url:
Streszczenie w PubMed:
DOI:
4/9
Andrew D. Zelenetz, Jacqueline C. Barrientos, Jennifer R. Brown, Bertrand Coiffier, Julio Delgado, Miklós Egyed, Paolo Ghia, Árpad Illes, Wojciech Jurczak, Paula Marlton, Marco Montillo, Franck Morschhauser, Alexander S. Pristupa, Tadeusz Robak, Jeff P. Sharman, David Simpson, Lukas Smolej, Eugen Tausch, Adeboye H. Adewoye, Lyndah K. Dreiling, Yeonhee Kim, Stephan Stilgenbauer, Peter Hillmen.
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.
Lancet. Oncology
2017 : Vol. 18, nr 3, s. 297-311, il., bibliogr. 22 poz., sum.
Autor korespondencyjny: Andrew D. Zelenetz.
p-ISSN: 1470-2045
AZ
ORG
AIF
IF: 36.418
Adres url:
Streszczenie w PubMed:
5/9
Peter Martin, Kami Maddocks, John P. Leonard, Jia Ruan, Andre Goy, Nina Wagner-Johnston, Simon Rule, Ranjana Advani, David Iberri, Tycel Phillips, Stephen Spurgeon, Eliana Kozin, Katherine Noto, Zhengming Chen, Wojciech Jurczak, Rebecca Auer, Ewa Chmielowska, Stephan Stilgenbauer, Johannes Bloehdorn, Craig Portell, Michael E. Williams, Martin Dreyling, Paul M. Barr, Selina Chen-Kiang, Maurizio DiLiberto, Richard R. Furman, Kristie A. Blum.
Postibrutinib outcomes in patients with mantle cell lymphoma.
Blood
2016 : Vol. 127, nr 12, s. 1559-1563, il., bibliogr. 14 poz., abstr.
p-ISSN: 0006-4971
AZ
ORG
AIF
IF: 13.164
Adres url:
Streszczenie w PubMed:
6/9
Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, Steven Coutre, John F. Seymour, Talha Munir, Soham D. Puvvada, Clemens-Martin Wendtner, Andrew W. Roberts, Wojciech Jurczak, Stephen P. Mulligan, Sebastian Böttcher, Mehrdad Mobasher, Ming Zhu, Monali Desai, Brenda Chyla, Maria Verdugo, Sari Heitner Enschede, Elisa Cerri, Rod Humerickhouse, Gary Gordon, Michael Hallek, William G. Wierda.
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
Lancet. Oncology
2016 : Vol. 17, nr 6, s. 768-778, il., bibliogr. 30 poz., sum.
p-ISSN: 1470-2045
AZ
ORG
AIF
IF: 33.900
Adres url:
Streszczenie w PubMed:
7/9
Michael L. Wang, Kristie A. Blum, Peter Martin, Andre Goy, Rebecca Auer, Brad S. Kahl, Wojciech Jurczak, Ranjana H. Advani, Jorge E. Romaguera, Michael E. Williams, Jacqueline C. Barrientos, Ewa Chmielowska, John Radford, Stephan Stilgenbauer, Martin Dreyling, Wieslaw Wiktor Jedrzejczak, Peter Johnson, Stephen E. Spurgeon, Liang Zhang, Linda Baher, Mei Cheng, Dana Lee, Darrin M. Beaupre, Simon Rule.
Long-term follow-up of MCL patients treated with single-agent ibrutinib: Updated safety and efficacy results.
Blood
2015 : Vol. 126, nr 6, s. 739-745, il., bibliogr. 14 poz., abstr.
p-ISSN: 0006-4971
AZ
ORG
AIF
IF: 11.847
Adres url:
Streszczenie w PubMed:
8/9
Wojciech Jurczak, Simon Rule, Peter Martin, Rebecca Auer, Brad S. Kahl, Agnieszka Giza, Bożena Jachimczak, Ranjana H. Advani, Jorge Romaguera, Michael Williams, Jacqueline Barrientos, Ewa Chmielowska, John Radford, Stephan Stilgenbauer, Jesse McGreivy, Fong Clow, Darrin M. Beaupre, Lori Kunkel, Andre Goy, Kristie A. Blum, Wiktor Jędrzejczak, Michael L. Wang.
Inhibitor kinazy Brutona u chorych z nawrotowym lub opornym na leczenie chłoniakiem z komórek płaszcza - wyniki międzynarodowego, wieloośrodkowego, badania II fazy z ibrutynibem (PCI-32765) - EHA Encore.
(Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma - Results of an International, Multicenter, Phase 2 Study of Ibrutinib (PCI-32765) - EHA Encore.)
Acta Haematologica Polonica
2013 : Vol. 44, nr 3, s. 314-318, il., bibliogr. 7 poz., abstr.
p-ISSN: 0001-5814
AP
ORG
KBN
Adres url:
DOI:
9/9
Michael L. Wang, Simon Rule, Peter Martin, Andre Goy, Rebecca Auer, Bras S. Kahl, Wojciech Jurczak, Ranjana H. Advani, Jorge E. Romaguera, Michael E. Williams, Jacqueline C. Barrientos, Ewa Chmielowska, John Radford, Stephan Stilgenbauer, Martin Dreyling, Wieslaw Wiktor Jedrzejczak, Peter Johnson, Stephen E. Spurgeon, Lei Li, Liang Zhang, Kate Newberry, Zhishuo Ou, Nancy Cheng, Bingliang Fang, Jesse McGreivy, Fong Clow, Joseph J. Buggy, Betty Y. Chang, Darrin M. Beaupre, Lori A. Kunkel, Kristie A. Blum.
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
New England Journal of Medicine
2013 : Vol. 369, nr 6, s. 507-516, il., bibliogr. 29 poz., abstr.
p-ISSN: 0028-4793
AZ
ORG
AIF
IF: 54.420
Adres url:
Wyświetl ponownie stosując format:

Wyświetl/ukryj etykiety | Wyświetlenie wyników w wersji do druku | Pobranie pliku do edytora | Nowe wyszukiwanie | Biblioteka Medyczna UJ